## AMENDMENTS TO THE CLAIMS

**This listing of claims will replace all prior versions and listings of claims in the application:**

## LISTING OF CLAIMS:

1. (Currently amended) A method of increasing the sensitivity of cancer cells or a tumour to a chemotherapeutic agent by contacting said cells or tumour with an isoflavonoid compound of formula (VI) or (VII):




(VI)




(VII)

~~(I):~~




(I)

~~in which~~ wherein

$R_1$, $R_2$ and Z are independently hydrogen, hydroxy, $OR_9$, $OC(O)R_{10}$, $OS(O)R_{10}$, CHO, $C(O)R_{10}$, COOH, $CO_2R_{10}$, $CONR_3R_4$, alkyl, haloalkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl, alkoxyaryl, thio, alkylthio, amino, alkylamino, dialkylamino, nitro or halo, or

$R_2$ is as previously defined, and $R_1$ and Z taken together with the carbon atoms to which they are attached form a five-membered ring selected from

, or

$R_1$ is as previously defined, and $R_2$ and Z taken together with the carbon atoms to which they are attached form a five-membered ring selected from



~~and~~

W is $R_1$, ~~A is hydrogen, hydroxy, $NR_3R_4$ or thio, and B is selected from~~



~~, or~~

~~W is $R_1$, and A and B taken together with the carbon atoms to which they are attached form a six-membered ring selected from~~



~~-or~~

~~W, A and B taken together with the groups to which they are associated are selected from~~



~~;-or~~

~~W and A taken together with the groups to which they are associated are selected from~~



~~and B is selected from~~




~~wherein~~

$R_3$ is hydrogen, alkyl, arylalkyl, alkenyl, aryl, an amino acid, $C(O)R_{11}$ where $R_{11}$ is hydrogen, alkyl, aryl, arylalkyl or an amino acid, or $CO_2R_{12}$ where ~~R12~~$R_{12}$ is hydrogen, alkyl, haloalkyl, aryl or arylalkyl,

$R_4$ is hydrogen, alkyl or aryl, or

$R_3$ and $R_4$ taken together with the nitrogen to which they are attached comprise pyrrolidinyl or piperidinyl,

~~$R_5$ is hydrogen, $C(O)R_{11}$ where $R_{11}$ is as previously defined, or $CO_2R_{12}$ where $R_{12}$ is as previously defined,~~

$R_6$ is hydrogen, hydroxy, alkyl, aryl, amino, thio, $NR_3R_4$, $COR_{11}$ where $R_{11}$ is as previously defined, $CO_2R_{12}$ where $R_{12}$ is as previously defined or $CONR_3R_4$,

~~$R_7$ is hydrogen, $C(O)R_{11}$ where $R_{11}$ is as previously defined, alkyl, haloalkyl, alkenyl, aryl, arylalkyl or $Si(R_{13})_3$ where each $R_{13}$ is independently hydrogen, alkyl or aryl,~~

~~$R_8$ is hydrogen, hydroxy, alkoxy or alkyl,~~

$R_9$ is alkyl, haloalkyl, aryl, arylalkyl, $C(O)R_{11}$ where $R_{11}$ is as previously defined, or $Si(R_{13})_3$ where $R_{13}$ ~~is as previously defined~~ where each $R_{13}$ is independently hydrogen, alkyl or aryl,

$R_{10}$ is hydrogen, alkyl, haloalkyl, amino, aryl, arylalkyl, an amino acid, alkylamino or dialkylamino,

the drawing "---" represents either a single bond or a double bond,

T is independently hydrogen, alkyl or aryl,

~~X is O, $NR_4$ or S, and~~

~~Y is~~




~~wherein~~

$R_{14}$, and $R_{15}$ ~~and $R_{16}$~~ are independently hydrogen, hydroxy, $OR_9$, $OC(O)R_{10}$, $OS(O)R_{10}$, CHO, $C(O)R_{10}$, COOH, $CO_2R_{10}$, $CONR_3R_4$, alkyl, haloalkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, thio, alkylthio, amino, alkylamino, dialkylamino, nitro or halo, or ~~any two of~~ $R_{14}$, and $R_{15}$ ~~and $R_{16}$~~ are fused together to form a cyclic alkyl, aromatic or heteroaromatic structure,

and pharmaceutically acceptable salts thereof, and

wherein the chemotherapeutic agent is platinum-based or anti-mitotic agent.

2. (Currently amended) A method of claim 1, wherein prior to the contacting, ~~the sensitivity of~~ the cancer cells or tumour were/was not sensitive to the chemotherapeutic agent ~~is restored~~.

3. (Currently amended) A method of claim 1, wherein the compound of formula [[(I)]](VI) or (VII) is administered to a subject in need of such treatment.

4. (Currently amended) A combination therapy for the treatment or prophylaxis of cell proliferation, cancer or a disease associated with oxidant stress comprising administering to a subject a therapeutically effective amount of a compound of formula [[(I)]](VI) or (VII) ~~as defined in claim 1~~ and a chemotherapeutic agent:




(VI)




(VII)

wherein

$R_1$, $R_2$ and Z are independently hydrogen, hydroxy, $OR_9$, $OC(O)R_{10}$, $OS(O)R_{10}$, CHO, $C(O)R_{10}$, COOH, $CO_2R_{10}$, $CONR_3R_4$, alkyl, haloalkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl, alkoxyaryl, thio, alkylthio, amino, alkylamino, dialkylamino, nitro or halo, or

$R_2$ is as previously defined, and $R_1$ and Z taken together with the carbon atoms to which they are attached form a five-membered ring selected from







, or

$R_1$ is as previously defined, and $R_2$ and Z taken together with the carbon atoms to which they are attached form a five-membered ring selected from







,

W is $R_1$,

$R_3$ is hydrogen, alkyl, arylalkyl, alkenyl, aryl, an amino acid, $C(O)R_{11}$ where $R_{11}$ is hydrogen, alkyl, aryl, arylalkyl or an amino acid, or $CO_2R_{12}$ where $R_{12}$ is hydrogen, alkyl, haloalkyl, aryl or arylalkyl,

$R_4$ is hydrogen, alkyl or aryl, or

$R_3$ and $R_4$ taken together with the nitrogen to which they are attached comprise pyrrolidinyl or piperidinyl,

$R_6$ is hydrogen, hydroxy, alkyl, aryl, amino, thio, $NR_3R_4$, $COR_{11}$ where $R_{11}$ is as previously defined, $CO_2R_{12}$ where $R_{12}$ is as previously defined or $CONR_3R_4$,

$R_9$ is alkyl, haloalkyl, aryl, arylalkyl, $C(O)R_{11}$ where $R_{11}$ is as previously defined, or $Si(R_{13})_3$ where $R_{13}$ where each $R_{13}$ is independently hydrogen, alkyl or aryl,

$R_{10}$ is hydrogen, alkyl, haloalkyl, amino, aryl, arylalkyl, an amino acid, alkylamino or dialkylamino,

the drawing "---" represents either a single bond or a double bond,

T is independently hydrogen, alkyl or aryl,

$R_{14}$, and $R_{15}$ are independently hydrogen, hydroxy, $OR_9$, $OC(O)R_{10}$, $OS(O)R_{10}$, CHO, $C(O)R_{10}$, COOH, $CO_2R_{10}$, $CONR_3R_4$, alkyl, haloalkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, thio, alkylthio, amino, alkylamino, dialkylamino, nitro or halo, or $R_{14}$ and $R_{15}$ are fused together to form a cyclic alkyl, aromatic or heteroaromatic structure,

and pharmaceutically acceptable salts thereof, and

wherein the chemotherapeutic agent is platinum-based or anti-mitotic agent.

5. (Canceled).

6. (Previously Presented) A method of claim 4, wherein the cancer is selected from breast cancer, prostatic cancer, testicular cancer, ovarian cancer, uterine cancer, pancreatic cancer and colorectal cancer.

7. (Original) A method claim 6, wherein the cancer is selected from ovarian cancer, prostatic cancer and pancreatic cancer.

8. (Currently amended) A method of claim 4, wherein the administration of the compound of formula [[(I)]](VI) or (VII) precedes the administration of the chemotherapeutic agent.

9. (Currently amended) A method of claim 4, wherein the administration of the compound of formula [[(I)]](VI) or (VII) and the chemotherapeutic agent is simultaneous.

10. (Previously Presented) A method claim 4, wherein the combination therapy follows observed resistance by cancer cells or tumour to a chemotherapeutic agent.

11.-12. (Canceled).

13. (Previously Presented) A method of claim 4, wherein the chemotherapeutic agent is cisplatin, paclitaxel or carboplatin.

14.-22. (Canceled).

23. (Currently amended) A pharmaceutical composition comprising a compound of formula [[(I)]](VI) or (VII) ~~of claim 1~~ and a chemotherapeutic agent:




(VI)




(VII)

wherein

$R_1$, $R_2$ and Z are independently hydrogen, hydroxy, $OR_9$, $OC(O)R_{10}$, $OS(O)R_{10}$, CHO, $C(O)R_{10}$, COOH, $CO_2R_{10}$, $CONR_3R_4$, alkyl, haloalkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl, alkoxyaryl, thio, alkylthio, amino, alkylamino, dialkylamino, nitro or halo, or

$R_2$ is as previously defined, and $R_1$ and Z taken together with the carbon atoms to which they are attached form a five-membered ring selected from

, or

$R_1$ is as previously defined, and $R_2$ and Z taken together with the carbon atoms to which they are attached form a five-membered ring selected from

,

W is $R_1$,

$R_3$ is hydrogen, alkyl, arylalkyl, alkenyl, aryl, an amino acid, $C(O)R_{11}$ where $R_{11}$ is hydrogen, alkyl, aryl, arylalkyl or an amino acid, or $CO_2R_{12}$ where $R_{12}$ is hydrogen, alkyl, haloalkyl, aryl or arylalkyl,

$R_4$ is hydrogen, alkyl or aryl, or

$R_3$ and $R_4$ taken together with the nitrogen to which they are attached comprise pyrrolidinyl or piperidinyl,

$R_6$ is hydrogen, hydroxy, alkyl, aryl, amino, thio, $NR_3R_4$, $COR_{11}$ where $R_{11}$ is as previously defined, $CO_2R_{12}$ where $R_{12}$ is as previously defined or $CONR_3R_4$,

$R_9$ is alkyl, haloalkyl, aryl, arylalkyl, $C(O)R_{11}$ where $R_{11}$ is as previously defined, or $Si(R_{13})_3$ where $R_{13}$ where each $R_{13}$ is independently hydrogen, alkyl or aryl,

$R_{10}$ is hydrogen, alkyl, haloalkyl, amino, aryl, arylalkyl, an amino acid, alkylamino or dialkylamino,

the drawing "---" represents either a single bond or a double bond,

T is independently hydrogen, alkyl or aryl,

$R_{14}$, and $R_{15}$ are independently hydrogen, hydroxy, $OR_9$, $OC(O)R_{10}$, $OS(O)R_{10}$, CHO, $C(O)R_{10}$, COOH, $CO_2R_{10}$, $CONR_3R_4$, alkyl, haloalkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, thio, alkylthio, amino, alkylamino, dialkylamino, nitro or halo, or $R_{14}$ and $R_{15}$ are fused together to form a cyclic alkyl, aromatic or heteroaromatic structure,

and pharmaceutically acceptable salts thereof, and

wherein the chemotherapeutic agent is platinum-based or anti-mitotic agent.

24. (Previously Presented): The pharmaceutical composition of claim 23, wherein said chemotherapeutic agent is cisplatin, paclitaxel or carboplatin.

25. (Canceled).

26. (New): The method of claim 1, wherein the cancer cells and tumour are/is hormone-responsive.

27. (New): The method of claim 1, wherein the cancer is selected from breast cancer, prostatic cancer, testicular cancer, ovarian cancer, uterine cancer, pancreatic cancer and colorectal cancer.

28. (New): The method of claim 1, wherein the cancer cells and tumour are/is from ovarian, prostate or pancreatic cancer.